InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $3.010 1.895 (169.96%)+
Announcement
Release
7 Nov 2025 8:27AM
Price at Release
$1.115
Full Release
download
Summary
AVITA Medical, Inc. presented its Q3 2025 financial and business update, highlighting a 13% year-over-year decline in revenue and a 24% reduction in operating expenses through disciplined cost management. The company's focus remains on expanding its presence in the U.S. market for burn, trauma, and surgical repair, which represents a $3.5 billion addressable market. AVITA has penetrated about 5% of this market, with RECELL being approved for treating thermal burn wounds and full-thickness skin defects. During the quarter, all seven Medicare Administrative Contractors (MACs) confirmed payment rates for RECELL, offering stability and confidence in reimbursement. The company also improved its net cash usage, reducing it to $6.2 million in Q3 from $10.1 million in the previous quarter. The strategic goals for Q4 include driving disciplined execution, refining commercial focus, and positioning for growth in 2026.
Key Points
  • Q3 2025 revenue decreased by 13% year-over-year.
  • Operating expenses reduced by 24% through cost management.
  • RECELL approved for treating burn wounds and full-thickness skin defects.
  • Confirmed payment rates from 7 MACs provide reimbursement stability.
  • U.S. addressable market for AVITA's products estimated at $3.5 billion.
  • Focused on penetrating ~200 top burn and trauma centers.
  • Improved net cash usage to $6.2 million in Q3.
  • Strategic focus on execution, commercial refinement, and future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.